BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,297,030 | -28.4% | 298,180 | -14.2% | 0.02% | -25.0% |
| Q2 2023 | $28,361,282 | +111064.0% | 347,437 | +1.0% | 0.03% | +3.2% |
| Q1 2023 | $25,513 | -3.9% | 343,894 | +7.3% | 0.03% | -13.9% |
| Q4 2022 | $26,556 | -99.9% | 320,414 | +310.7% | 0.04% | +9.1% |
| Q3 2022 | $22,157,000 | -15.7% | 78,016 | +2.9% | 0.03% | -13.2% |
| Q2 2022 | $26,270,000 | -18.2% | 75,784 | +2.2% | 0.04% | -7.3% |
| Q1 2022 | $32,114,000 | -15.4% | 74,160 | +1.0% | 0.04% | -12.8% |
| Q4 2021 | $37,976,000 | +9.0% | 73,406 | +2.0% | 0.05% | 0.0% |
| Q3 2021 | $34,856,000 | -33.0% | 71,932 | -37.8% | 0.05% | -30.9% |
| Q2 2021 | $52,051,000 | +15.2% | 115,601 | -2.3% | 0.07% | +11.5% |
| Q1 2021 | $45,180,000 | +17.8% | 118,293 | -2.1% | 0.06% | +15.1% |
| Q4 2020 | $38,365,000 | +24.4% | 120,815 | -3.0% | 0.05% | +10.4% |
| Q3 2020 | $30,852,000 | -14.1% | 124,539 | -8.4% | 0.05% | -20.0% |
| Q2 2020 | $35,907,000 | +49.5% | 135,974 | +7.3% | 0.06% | +20.0% |
| Q1 2020 | $24,021,000 | -9.3% | 126,679 | +5.0% | 0.05% | +13.6% |
| Q4 2019 | $26,474,000 | +11.4% | 120,606 | -0.7% | 0.04% | +2.3% |
| Q3 2019 | $23,765,000 | -7.9% | 121,457 | -1.9% | 0.04% | -10.4% |
| Q2 2019 | $25,806,000 | +4.0% | 123,776 | -0.9% | 0.05% | 0.0% |
| Q1 2019 | $24,802,000 | +33.5% | 124,918 | -2.7% | 0.05% | +20.0% |
| Q4 2018 | $18,572,000 | -10.2% | 128,331 | +26.7% | 0.04% | 0.0% |
| Q3 2018 | $20,680,000 | +40.5% | 101,317 | +1.9% | 0.04% | +33.3% |
| Q2 2018 | $14,715,000 | -2.4% | 99,459 | -0.4% | 0.03% | -3.2% |
| Q1 2018 | $15,075,000 | +30.6% | 99,809 | +12.0% | 0.03% | +34.8% |
| Q4 2017 | $11,542,000 | +5.4% | 89,090 | -1.7% | 0.02% | -4.2% |
| Q3 2017 | $10,955,000 | -8.5% | 90,617 | -11.1% | 0.02% | -11.1% |
| Q2 2017 | $11,977,000 | +14.4% | 101,933 | -1.0% | 0.03% | +12.5% |
| Q1 2017 | $10,469,000 | -0.3% | 102,993 | +0.9% | 0.02% | -11.1% |
| Q4 2016 | $10,498,000 | -3.9% | 102,087 | +2.4% | 0.03% | -10.0% |
| Q3 2016 | $10,920,000 | -4.2% | 99,722 | -1.3% | 0.03% | -11.8% |
| Q2 2016 | $11,399,000 | +25.8% | 101,086 | +5.5% | 0.03% | +21.4% |
| Q1 2016 | $9,058,000 | +9.0% | 95,829 | +3.8% | 0.03% | +3.7% |
| Q4 2015 | $8,310,000 | -0.8% | 92,329 | +1.9% | 0.03% | -3.6% |
| Q3 2015 | $8,375,000 | -11.3% | 90,584 | -5.5% | 0.03% | -6.7% |
| Q2 2015 | $9,443,000 | +0.6% | 95,899 | +2.4% | 0.03% | +11.1% |
| Q1 2015 | $9,389,000 | +17.8% | 93,618 | +8.5% | 0.03% | +17.4% |
| Q4 2014 | $7,973,000 | -0.2% | 86,286 | +1.1% | 0.02% | -4.2% |
| Q3 2014 | $7,985,000 | – | 85,351 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |